Literature DB >> 29412494

The rising tide of Acanthamoeba keratitis in Auckland, New Zealand: a 7-year review of presentation, diagnosis and outcomes (2009-2016).

James McKelvie1,2, Moaz Alshiakhi2, Mohammed Ziaei1,2, Dipika V Patel1,2, Charles Nj McGhee1,2.   

Abstract

IMPORTANCE: Acanthamoeba is an increasingly prevalent cause of vision-threatening microbial keratitis.
BACKGROUND: To assess the incidence, clinical presentation, diagnosis and outcomes of patients with Acanthamoeba keratitis (AK) in Auckland, New Zealand over a 7-year period.
DESIGN: Retrospective observational consecutive case series. PARTICIPANTS: Fifty-eight eyes of 52 patients diagnosed with AK.
METHODS: All cases of AK were identified using a cross-referenced search of clinical, laboratory and pharmacy records from March 2009 to May 2016. MAIN OUTCOME MEASURES: Demographic and clinical data were collected including age, gender, risk factors, clinical manifestations, initial diagnosis, diagnostic investigations, treatment, presenting and final visual acuity and surgical interventions.
RESULTS: Contact lens (CL) use was noted in 96% of unilateral and 100% of bilateral cases. The mean duration of symptoms at presentation was 21 days and the mean duration from presentation to definitive diagnosis was 14 days. Initial diagnosis was recorded as CL-related keratitis in 70.6%, viral keratitis in 15.5% and AK in 12.0%. The diagnosis was confirmed with In vivo confocal microscopy (IVCM) in 67.2%, corneal scrape in 22.4%, corneal biopsy in 1.7% and clinically in 8.6%. IVCM sensitivity was 83.0%. Surgical intervention was required in four patients, all with delayed diagnosis (range 63-125 days). The incidence of AK has more than doubled when compared with the preceding 7-year period. CONCLUSIONS AND RELEVANCE: AK is a rare vision-threatening protozoal infection with rapidly-increasing incidence in New Zealand, predominantly affecting CL users. Diagnosis is often challenging and when delayed is associated with worse outcomes. IVCM offers rapid diagnosis with high sensitivity.
© 2018 Royal Australian and New Zealand College of Ophthalmologists.

Entities:  

Keywords:  acanthamoeba; contact lens; in vivo confocal microscopy; keratitis

Mesh:

Year:  2018        PMID: 29412494     DOI: 10.1111/ceo.13166

Source DB:  PubMed          Journal:  Clin Exp Ophthalmol        ISSN: 1442-6404            Impact factor:   4.207


  6 in total

1.  Tannic acid-modified silver nanoparticles as a novel therapeutic agent against Acanthamoeba.

Authors:  Marcin Padzik; Edyta B Hendiger; Lidia Chomicz; Marta Grodzik; Maciej Szmidt; Jarosław Grobelny; Jacob Lorenzo-Morales
Journal:  Parasitol Res       Date:  2018-08-15       Impact factor: 2.289

2.  Application of Histone Deacetylase Inhibitors MPK472 and KSK64 as a Potential Treatment Option for Acanthamoeba Keratitis.

Authors:  Hae-Ahm Lee; So-Min Park; Ki-Back Chu; Fu-Shi Quan; Thomas Kurz; Marc Pflieger; Eun-Kyung Moon
Journal:  Antimicrob Agents Chemother       Date:  2020-11-17       Impact factor: 5.191

3.  Risk factors and clinical signs of severe Acanthamoeba keratitis.

Authors:  Machiko Shimmura-Tomita; Hiroko Takano; Nozomi Kinoshita; Fumihiko Toyoda; Yoshiaki Tanaka; Rina Takagi; Mina Kobayashi; Akihiro Kakehashi
Journal:  Clin Ophthalmol       Date:  2018-12-10

4.  Evaluation of Acanthamoeba keratitis cases in a tertiary medical care centre over 21 years.

Authors:  Wolfgang List; Wilfried Glatz; Regina Riedl; Georg Mossboeck; Gernot Steinwender; Andreas Wedrich
Journal:  Sci Rep       Date:  2021-01-13       Impact factor: 4.379

Review 5.  The biology of Acanthamoeba keratitis.

Authors:  Jerry Y Niederkorn
Journal:  Exp Eye Res       Date:  2020-11-19       Impact factor: 3.467

6.  The rising incidence of Acanthamoeba keratitis: A 7-year nationwide survey and clinical assessment of risk factors and functional outcomes.

Authors:  Anna C Randag; Jeroen van Rooij; Arnoud T van Goor; Samuël Verkerk; Robert P L Wisse; Isabelle E Y Saelens; Remco Stoutenbeek; Bart T H van Dooren; Yanny Y Y Cheng; Cathrien A Eggink
Journal:  PLoS One       Date:  2019-09-06       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.